IgA nephropathy in a patient with ankylosing spondylitis well controlled with etanercept.
- Author:
Do Hyeong LEE
1
;
Geun Tae KIM
;
Na Kyoung HWANG
;
Eun Heui KIM
Author Information
- Publication Type:Case Report
- Keywords: Ankylosing spondylitis; IgA glomerulonephritis; Tumor necrosis factor alpha
- MeSH: Adult; Biopsy; Etanercept*; Glomerulonephritis, IGA*; Hematuria; Humans; Immunoglobulin A*; Joints; Kidney; Male; Necrosis; Proteinuria; Skin; Spondylitis, Ankylosing*; Tumor Necrosis Factor-alpha
- From:Kosin Medical Journal 2018;33(1):85-90
- CountryRepublic of Korea
- Language:English
- Abstract: Ankylosing spondylitis (AS) can involve the eye, gastrointestinal system, cardiopulmonary system, skin, kidneys, and spinal and peripheral joints. It is rarely accompanied by immunoglobulin A (IgA) nephropathy. Although IgA is involved in both AS and IgA nephropathy, the relationship between these diseases remains unclear. We detected hematuria and proteinuria in a 32-year-old male patient with ankylosing spondylitis that remained stable for 4 years through treatment with etanercept, a tumor necrosis factor-α (TNF-α) inhibitor, and diagnosed IgA nephropathy through a renal biopsy. IgA nephropathy seems to be less commonly associated with AS disease activity or specific treatment such as TNF-α inhibitor use.
